(19) INDIA

(51) International

(86) International

(87) International

Publication No

Filing Date

Filing Date

Application Number

Filing Date

(62) Divisional to

(61) Patent of Addition:NA to Application Number :NA

Application No

classification

(22) Date of filing of Application :26/11/2022

A61K0045060000

:PCT//

: NA

:NA

:NA

:01/01/1900

(43) Publication Date: 02/12/2022

(54) Title of the invention: A Lead compound Deserpidine as inhibitor of efflux-mediated multidrug resistance

(71)Name of Applicant:

1)Brainware University

Address of Applicant :398, Ramkrishnapur Rd, Near Jagadighata Market, Barasat, Kolkata, West Bengal 700125 -----

:A61P0033060000, C07K0014705000, Name of Applicant: NA A61K0031495000, A61K0031352000, Address of Applicant: NA (72) Name of Inventor: 1)Dr. Abhishek Jana

> Address of Applicant : Associate Professor, Department of Allied Health Sciences, Brainware University, 398, Ramkrishnapur Rd, near Jagadighata Market, Barasat, Kolkata, West Bengal 700125 -

2)Dr. Pratiti Ghosh

Address of Applicant : Professor, Department of Physiology, West Bengal State University, North 24 Parganas, Malikapur,

Berunanpukuria, Barasat, Kolkata, West Bengal 700126 -----

3)Ms. Chandana Roy

Address of Applicant: Student, Department of Physiology, West Bengal State University, North 24 Parganas, Malikapur, Berunanpukuria, Barasat, Kolkata, West Bengal 700126 -----

(57) Abstract:

The present invention discloses a Lead compound Deserpidine as inhibitor of efflux-mediated multidrug resistance. The present invention refers Descriptine is a competitive inhibitor of p-glycoprotein and cytochrome P450 3A4 (CYP3A4) and has acceptable drug-like properties. The compound can inhibit the activity of drug efflux transporter P-glycoprotein which is commonly expressed in different types of cancer cells, malaria, and tuberculosis types of diseases. In the present days, expression of P-glycoprotein is one of the main reasons for treatment failure, so Deserpidine can be used for the development of new drugs to prevent the activity of Pglycoprotein and the efficacy of the chemotherapy can be increased.

No. of Pages: 14 No. of Claims: 4